Physician profile
Ruth Tang
NPI 1043283500
$12,542.21
in general payments reported to CMS, 2019-2025
12 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 87% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,675 · 2020: $808 · 2021: $1,137 · 2022: $4,115 · 2023: $1,561 · 2024: $1,093 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,649 · Debt Forgiveness: $121 · Entertainment: $36.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,649.46 |
| Debt Forgiveness | $121.14 |
| Entertainment | $36.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $6,700.19 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $2,211.17 | 2019-2023 | Total30, Precision 1 |
| Johnson & Johnson Vision Care, INC. | $2,087.77 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $354.83 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $281.91 | 2021 | |
| Bausch & Lomb Americas INC. | $204.93 | 2022-2024 | Infuse |
| Glaukos Corporation | $189.95 | 2025 | Istent Infinite, Idosetr |
| Allergan, INC. | $150.33 | 2021-2022 | |
| Sight Sciences, INC. | $123.75 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $121.14 | 2024 | |
| Visioneering Technologies, INC. | $80.07 | 2019-2023 | |
| Optos, INC. | $36.17 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.